Advanced searches left 3/3

Methotrexate Rheumatoid Arthritis - Europe PMC

Summarized by Plex Scholar
Last Updated: 02 May 2022

* If you want to update the article please login/register

Targeted delivery of methotrexate by modified yeast β-glucan nanoparticles for rheumatoid arthritis therapy

For preparing BYG-based nanoparticles and systemic toxicity for treating rheumatoid arthritis, we used linear glucans from yeast with good biocompatibility and targetability to macrophages. Due to a decrease of disulfide bonds by glutathione, methotrexate-loaded cBP nanoparticles with the drug loading efficiency of 23. 7% was able to linearly release methotrexate. Cell experiments show that cBP nanoparticles were effectively internalized into macrophages due to the targetability.

Source link: https://europepmc.org/article/MED/IND607659870


Pharmacokinetics, Pharmacodynamics and Safety of Single-Dose Subcutaneous Sarilumab With or Without Methotrexate in Japanese Patients with Rheumatoid Arthritis: Two Single-Dose Studies.

Objects: To investigate the pharmacokinetics and pharmacokinetics of single-dose subcutaneous sarilumab or tocilizumab SC; methotrexate; to determine the pharmacokinetics of sarilumab SC or tocilizumab SC monotherapy in Japanese rheumatoid arthritis patients. PK profiles of single-dose sarilumab 150 mg or tocilizumab 162 mg were similar; however, there were some numerical differences in PD profiles and TEAEs, which were not as evident. Both studies found that the most commonly reported TEAE with sarilumab treatment was decreasing/neutropenia. Conclusions PK, PD, and safety profiles of single-dose sarilumab SC with or without methotrexate were all consistent with expected findings in Japanese patients with RA.

Source link: https://europepmc.org/article/MED/35445719


Exhaled nitric oxide in early rheumatoid arthritis and effects of methotrexate treatment.

The purpose of this research was to investigate the NO lung dynamics in patients with new onset RA before and after immune suppression with methotrexate therapy. Disease Activity Score (28 joints) was used to determine clinical disease prevalence in 28 joints. C A NO was lower in RA patients 1. 6 ppb compared to the control group's 2. 3 ppb, p = 0. 007. The RA patients' 55 ppb was also lower in comparison to control subjects' 124 ppb, p 0. 001, but D aw NO was still higher 17 mL/s and 9 mL/s respectively, p 0. 001, but D aw NO was also lower in the RA patients' 55 ppb, p 0. 001, but D aw NO was also higher in the RA patients' 84 a t a b, a compared to control subjects's, p a a, s a t a mL/s and 9 aw 9 mL/s, a t a b, a aw a mL/s and 9 mL/s a aw mL/s and 9 aw NO was also lower, aw t aw z t s mL/s and 9 In conclusion, the improved NO dynamics of the lung in ACPA-positive RA patients are still present in the early stages of the disease before any treatment and do not change after methotrexate therapy, which has been implicated in the pathogenesis.

Source link: https://europepmc.org/article/MED/35444250


Treatment of early rheumatoid arthritis: Methotrexate and beyond.

Methotrexate has been used for the first treatment of rheumatoid arthritis for the first two decades. Methotrexate is generally well tolerated, but it does have some important, albeit rare, side-effects, such as a risk of liver disease and cytopenias. Some studies have shown that more active monitoring in patients with fatty liver disease may be more useful. Methotrexate is still being marketed as a first-line therapy, according to new published studies.

Source link: https://europepmc.org/article/MED/35453032


Methotrexate significantly reduces the humoral vaccination response against SARS-CoV-2 in older but not younger patients with rheumatoid arthritis.

To determine the humoral reaction to vaccination against SARS-CoV-2 in patients with rheumatoid arthritis treated with methotrexate. SARS-CoV-2's primary aim was to determine the humoral immune response as measured by titres of neutralizing antibodies against the S1 antigen. Patients' subgroups with and without methotrexate exposure were compared in a cross-sectional, single-centre research. Fortunately, patients in the oldest patient subgroup with a significantly reduced humoral response to vaccination, according to a study by MTX and non-MTX patients, with titres of neutralizing antibodies not significantly different between MTX and non-MTX patients in patients under the age of 70 years of age. In patients over 70 years of non-MTX patients, the maximum immune response was present in 76. 5% of cases, but this percentage was down to 56. 7 percent in study participants on MTX drugs. After vaccination against SARS-CoV-2, a patient with rheumatoid arthritis in conjunction with methotrexate findings in a dramatically reduced humoral response.

Source link: https://europepmc.org/article/MED/35429290


The Impact of Traditional Chinese Medicine QingreHuoxue Treatment and the Combination of Methotrexate and Hydroxychloroquine on the Radiological Progression of Active Rheumatoid Arthritis: A 52-Week Follow-Up of a Randomized Controlled Clinical Study.

QingreHuoxue therapy is a Chinese medicine therapy for RA. To date, only few studies have compared the long-term effects of QRHXD to those of traditional disease-modifying antirheumatic agents on RA disease activity and radiological progression. The Clinical Indicators and Imaging results from baseline to week 52 were examined by a portion of the patients in "Traditional Chinese Medicine QingreHuoj Trial vs. the Combination of Methotrexate and Hydrochloroquine for Active Rheumatoid Arthritis" research, as well as the intention-to-treat and compliance protocols. There were no significant differences between the three groups: the traditional Chinese medicine integrative care group, the Western medicine research group, and the integrated traditional Chinese and Western medicine treatment group.

Source link: https://europepmc.org/article/MED/35463097


Associations Between Genetic Polymorphisms Within Transporter Genes and Clinical Response to Methotrexate in Chinese Rheumatoid Arthritis Patients: A Pilot Study.

In Chinese rheumatoid arthritis patients, the primary aim was to investigate the connection between genetic polymorphisms within transporter genes and clinical reaction to methotrexate. Patients and methods Patients undergoing treatment A total of 100 RA patients receiving MTX were prospectively followed up for approximately three months to determine the clinical response based on several factors, including European League Against Rheumatism good and moderate response, disease burden in 28 joint counts, and elevation of DAS28-ESR > 0. 6. Compared to the most common haplotype CCC, the ABCC2 haplotype TTT, consisting of rs717620, rs4148396, and rs3740066 was highly associated with EULAR high and moderate responses, with a 0. 6 percent at R. 7620, rs4148396 and rs3740066 was highly linked to EULAR positive and moderate responses, including TTT as a result. Conclusions Our results show that genetic polymorphisms within transporter genes, especially SLC19A1 and ABCC2, could be predictors of Chinese RA patients' clinical response to MTX.

Source link: https://europepmc.org/article/MED/35437350


Development of a Novel Methotrexate-Loaded Nanoemulsion for Rheumatoid Arthritis Treatment with Site-Specific Targeting Subcutaneous Delivery.

Rheumatoid arthritis, a systemic, chronic autoimmune disease, causes disability due to persistent inflammation and tissue damage in the joints. The biggest issue in treating RA with methotrexate is the systemic side effects that minimize dose escalation. Hence, a novel formulation of a methotrexate-loaded nanoemulsion for subcutaneous administration was devised that aims to introduce methotrexate into the system via the lymph. The crystalline methotrexate was converted to an amorphous form by the DSC's review, and the drug was completely integrated into the vesicles. The nanoemulsion was non-toxic, according to MTT's cytocompatibility testing, which was based on macrophage cell lines. In addition, the methotrexate nanoemulsion containing methotrexate remained stable for three months after being stored at a low temperature. It is a popular drug delivery method for subcutaneous drug delivery since the nanoemulsion containing methotrexate has excellent physicochemical properties and reduces systemic side effects by targeted delivery.

Source link: https://europepmc.org/article/MED/35458007


Influence of Concomitant Methotrexate use on the Clinical Effectiveness, Retention, and Safety of Abatacept in Biologic-Naïve Patients with Rheumatoid Arthritis: Post-hoc Subgroup Analysis of ORIGAMI Study.

Objectives We performed post-hoc reviews of the ORIGAMI study to see if concomitant methotrexate influences the clinical results of abatacept in biologic-nave patients with rheumatoid arthritis. The evolution of Simplified Disease Activity Index (C-reactive protein), Disease Activity Score-28 with C-reactive protein, and the Japanese Health Assessment Questionnaire were compared through to 52 weeks of therapy, the abatacept retention rate, and safety. Results In the MTX- and MTX+ groups, the mean SDAI, DAS28-CRP, and J-HAQ scores were similar in Week 52. No significant correlation was found between MTX use and SDAI or J-HAQ, according to a multivariable logistic regression study.

Source link: https://europepmc.org/article/MED/35389481


Disease activity and therapeutic drug monitoring of polyglutamates of methotrexate after daily or weekly administration of low-dose methotrexate in patients recently diagnosed with rheumatoid arthritis.

Patients from groups A and B showed a positive response to methotrexate therapy in 29 percent and 25. 5%, respectively, with a worldwide incidence of adverse events of 38 percent. Without differences between dosage groups, Methotrexate polyglutamate 3 concentrations were higher in normal weight than in obese patients, with a median of 28 and 10. 35 nM. Methotrexate polyglutamate 3 concentrations, which exhibits a non-competitive and safe manner in comparison to a weekly dose regimen, could be a useful tool for therapeutic drug monitoring purposes.

Source link: https://europepmc.org/article/MED/35365958

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions